Press Releases
September 4, 2025
Media Update: ERS: new data across Sanofi’s immunology pipeline reinforce leadership in respiratory diseases
September 4, 2025
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
September 3, 2025
Media Update: EADV: Sanofi builds on legacy in immunology with new data highlighting advances in treatment of chronic inflammatory skin diseases
Upcoming Events
Past Events
31Jul
2025
Second Quarter 2025
Second quarter 2025 results were reviewed by management during a live audio webcast with the financial community on July 31, 2025. The presentation was followed by a Q&A session.
Quarterly results
24Apr
2025
First quarter 2025
First quarter 2025 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.
Quarterly results
30Jan
2025
Fourth Quarter & Full Year 2024 Results
Fourth quarter and full year 2024 results were reviewed by management during a live audio webcast with the financial community on January 30, 2025. The presentation was followed by a Q&A session.
15:00 - 16:30 CET (9:00am – 10:30am EST)
Quarterly results